MedTrace Logo

Adding Phosphorus to Osteoporosis Drug Treatment

NCT00074711 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 241

Last updated 2016-07-06

Study results available
· View outcomes & findings →

Summary

Osteoporosis causes bones to weaken and break more easily. Calcium and phosphorus are two minerals that are essential for normal bone formation. Unfortunately, calcium salts commonly prescribed in anti-osteoporosis treatment bind phosphorus from food and restrict phosphorus available for bone building. Teriparatide is a drug that reduces the risk of fractures by increasing bone thickness and strength. Vitamin D is also necessary for strong bones and teeth. The purpose of this study is to evaluate the bone-building effectiveness of two calcium supplements, one with a source of phosphorus and one without, in combination with teriparatide and vitamin D in women with osteoporosis.

Conditions

Interventions

DRUG

Calcium carbonate

Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium carbonate.

DRUG

Calcium Phosphate

Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium phosphate.

Sponsors & Collaborators

  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

    collaborator NIH

  • Office of Dietary Supplements (ODS)

    collaborator NIH

  • Creighton University

    lead OTHER

Principal Investigators

  • Robert P. Heaney, MD · Creighton University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
85 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-31
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00074711 on ClinicalTrials.gov